Taekyu Ha

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10452208/publications.pdf

Version: 2024-02-01

1478505 1372567 11 95 10 6 citations h-index g-index papers 11 11 11 204 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Potential Dual Role of Activating Transcription Factor 3 in Colorectal Cancer. Anticancer Research, 2016, 36, 509-16.	1.1	18
2	Effects of DLC1 Deficiency on Endothelial Cell Contact Growth Inhibition and Angiosarcoma Progression. Journal of the National Cancer Institute, 2018, 110, 390-399.	6.3	13
3	DLC1 deficiency and YAP signaling drive endothelial cell contact inhibition of growth and tumorigenesis. Oncogene, 2019, 38, 7046-7059.	5.9	13
4	Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth. EMBO Molecular Medicine, 2021, 13, e14089.	6.9	13
5	Identification of Eph receptor signaling as a regulator of autophagy and a therapeutic target in colorectal carcinoma. Molecular Oncology, 2019, 13, 2441-2459.	4.6	11
6	Tolfenamic acid downregulates \hat{l}^2 -catenin in colon cancer. International Immunopharmacology, 2016, 35, 287-293.	3.8	8
7	ESE‑1 suppresses the growth, invasion and migration of human NSCLC cells and tumor formation in�vivo. Oncology Reports, 2018, 40, 1734-1742.	2.6	8
8	Identification of epithelialâ€specific ETSâ€1 (ESEâ€1) as a tumor suppressor and molecular target of green tea compound, EGCG. Molecular Carcinogenesis, 2019, 58, 922-932.	2.7	5
9	Novel insights into endothelial cell malignancies. Oncotarget, 2018, 9, 37468-37470.	1.8	4
10	Antisense transcription from lentiviral gene targeting linked to an integrated stress response in colorectal cancer cells. Molecular Therapy - Nucleic Acids, 2022, 28, 877-891.	5.1	2
11	ESEâ€1 Represses Formation of Tumor in vivo and Growth, Invasion and Migration of Human NSCLC Cells in vitro. FASEB Journal, 2018, 32, 668.5.	0.5	O